245sek
1,7 %
Date:2025-06-05Time:18:00:00Latest report:Q4-2024List:First NorthTicker:COMBI
Market Cap:49 msekEnterprise Value:-25 msekNet Sales:0,33 msekEarnings:-44,9 msekEmployees:0ISIN:SE0016101935

Ratios

10-year key figure history for CombiGene turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for CombiGene with index and moving average MA50 and MA200.

Stockprice:2,45
MA50:2,45
MA200:2,48
Price/MA200:-1,2 %
RSI (14):49,1
Price/MA50:0,1 %

Description

CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.

Biotechnology